enGene Therapeutics Inc. (ENGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $161.51M
Last updated: Nov 17, 2026 at 11:05 AM ET
enGene Therapeutics Inc. (ENGN) Earnings: Report Dates and Results
enGene Therapeutics (ENGN) is expected to report earnings on Dec 22, 2026. In the quarter ended Jul 31, 2026, enGene Therapeutics reported EPS of $0.47, above the -$0.44 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ENGN has an expected report date of Dec 22, 2026.
Earnings History
Of the 11 quarters below that had an estimate, ENGN beat 6 and missed 5. The widest gap in the table came in the quarter ended Jul 31, 2026, when EPS landed 206.82% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | $0.47 | -$0.44 | -$0.51 - -$0.35 | +206.82% | Beat | N/A | 8 | 8 up, 0 down | Sep 8, 2026 |
| Apr 30, 2026 | -$0.43 | -$0.48 | -$0.51 - -$0.44 | +10.42% | Beat | N/A | 9 | 2 up, 1 down | Jun 15, 2026 |
| Jan 31, 2026 | -$0.44 | -$0.57 | -$0.65 - -$0.48 | +23.32% | Beat | N/A | 8 | 3 up, 2 down | Mar 9, 2026 |
| Oct 31, 2025 | -$0.73 | -$0.58 | -$0.63 - -$0.52 | -25.86% | Miss | N/A | 8 | 0 up, 1 down | Dec 22, 2025 |
| Jul 31, 2025 | -$0.57 | -$0.51 | -$0.57 - -$0.43 | -11.76% | Miss | N/A | 8 | 3 up, 3 down | Sep 10, 2025 |
| Apr 30, 2025 | -$0.51 | -$0.48 | -$0.60 - -$0.32 | -6.25% | Miss | N/A | 9 | 0 up, 5 down | Jun 12, 2025 |
| Jan 31, 2025 | -$0.48 | -$0.37 | -$0.43 - -$0.31 | -29.73% | Miss | N/A | 9 | 3 up, 0 down | Mar 10, 2025 |
| Oct 31, 2024 | -$0.34 | -$0.36 | -$0.45 - -$0.25 | +5.56% | Beat | N/A | 7 | 1 up, 0 down | Dec 19, 2024 |
| Jul 31, 2024 | -$0.32 | -$0.35 | -$0.52 - -$0.17 | +8.57% | Beat | N/A | 6 | 0 up, 0 down | Sep 10, 2024 |
| Apr 30, 2024 | -$0.38 | -$0.27 | -$0.35 - -$0.20 | -40.74% | Miss | N/A | 5 | 0 up, 0 down | Jun 14, 2024 |
| Jan 31, 2024 | -$0.46 | -$0.47 | N/A | +2.13% | Beat | -1250.0% | N/A | N/A | Mar 11, 2024 |
| Oct 31, 2023 | -$4.51 | N/A | N/A | N/A | N/A | -11609.9% | N/A | N/A | Jan 29, 2024 |
| Jul 31, 2023 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 31, 2023 |
| Apr 30, 2023 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2023 |
| Jan 31, 2023 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 30, 2023 |
| Oct 31, 2022 | $0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2022 |
| Jul 31, 2022 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2022 |
| Apr 30, 2022 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 13, 2022 |
| Jan 31, 2022 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 30, 2022 |
| Oct 31, 2021 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Dec 30, 2021 |
Annual EPS
EPS for the fiscal year ended Oct 31, 2026 was -$0.40, after -$2.29 the year before. It was -$0.02 for the year ended Oct 31, 2022, the oldest of the 5 fiscal years below with reported EPS.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Oct 31, 2026 | -$0.40 | N/A |
| Oct 31, 2025 | -$2.29 | N/A |
| Oct 31, 2024 | -$1.50 | N/A |
| Oct 31, 2023 | -$4.65 | N/A |
| Oct 31, 2022 | -$0.02 | N/A |
| Oct 31, 2021 | Not reported | N/A |
Frequently Asked Questions About ENGN
When is enGene Therapeutics's next earnings date?
enGene Therapeutics's next earnings report is expected for Dec 22, 2026.
Did ENGN beat earnings estimates last quarter?
Yes. enGene Therapeutics reported EPS of $0.47 for the quarter ended Jul 31, 2026, above the -$0.44 estimate, a 206.82% surprise.
What EPS do analysts expect from ENGN next quarter?
The consensus EPS estimate for enGene Therapeutics for the quarter ended Oct 31, 2026 is -$0.47 from 11 analysts, with estimates from -$0.54 to -$0.38.
How often does ENGN beat earnings estimates?
enGene Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +21.56%.
ENGN pages: Overview, Earnings, Forecast, Financials, Competitors